Sven Rohmann

Sven Rohmann currently works at Bio Vitos Pharma AB, as Chief Executive Officer from 2025, Hervolution ApS, as Director, Center for Molecular Medicine (Sweden), as Chief Business Development Officer, and Tcer AB, as Chief Business Development Officer.
Dr. Rohmann also formerly worked at Ganymed Pharmaceuticals AG, as Chief Executive Officer, Vivesto AB, as Chief Executive Officer & Director from 2019 to 2020, Biovision AG, as Chief Executive Officer, Mendus AB, as Chief Executive Officer from 2020 to 2021, Adiuvo Investment SA, as Chief Executive Officer, Helix BioPharma Corp., as Chairman in 2017, ImVisioN GmbH, as Chairman, Helix Polska Sp zoo, as Chairman, LifeMD, Inc., as Director & Co-Chief Medical Officer-Global from 2015 to 2017, Burrill LLC, as General Manager-Europe Region, Nextech Invest AG, as General Partner, ArcticZymes Technologies ASA, as Vice President, Pantec Biosolutions AG, as Chief Business Officer, and Novartis Pharma AG, as Fund Manager.
Dr. Rohmann received his doctorate degree from Erasmus University Rotterdam, doctorate degree from The Johannes Gutenberg University of Mainz, and Masters Business Admin degree from Kellogg School of Management.